Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine
Clinical and Vaccine Immunology, Volume 18, No. 3, Year 2011
Notification
URL copied to clipboard!
Description
The serogroup A meningococcal conjugate vaccine MenAfriVac has the potential to confer herd immunity by reducing carriage prevalence of epidemic strains. To better understand this phenomenon, we initiated a meningococcal carriage study to determine the baseline carriage rate and serogroup distribution before vaccine introduction in the 1- to 29-year old population in Burkina Faso, the group chosen for the first introduction of the vaccine. A multiple cross-sectional carriage study was conducted in one urban and two rural districts in Burkina Faso in 2009. Every 3 months, oropharyngeal samples were collected from >5,000 randomly selected individuals within a 4-week period. Isolation and identification of the meningococci from 20,326 samples were performed by national laboratories in Burkina Faso. Confirmation and further strain characterization, including genogrouping, multilocus sequence typing, and porA-fetA sequencing, were performed in Norway. The overall carriage prevalence for meningococci was 3.98%; the highest prevalence was among the 15- to 19-year-olds for males and among the 10- to 14-year-olds for females. Serogroup Y dominated (2.28%), followed by serogroups X (0.44%), A (0.39%), and W135 (0.34%). Carriage prevalence was the highest in the rural districts and in the dry season, but serogroup distribution also varied by district. A total of 29 sequence types (STs) and 51 porA-fetA combinations were identified. The dominant clone was serogroup Y, ST-4375, P1.5-1,2-2/F5-8, belonging to the ST-23 complex (47%). All serogroup A isolates were ST-2859 of the ST-5 complex with P1.20,9/F3-1. This study forms a solid basis for evaluating the impact of MenAfriVac introduction on serogroup A carriage. Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Authors & Co-Authors
Kristiansen, Paul Arne
Norway, Oslo
Folkehelseinstituttet
Diomandé, Fabien V.K.
Burkina Faso, Ouagadougou
World Health Organization Ouagadougou
United States, Atlanta
Centers for Disease Control and Prevention
Wei, Stanley C.
United States, Atlanta
Centers for Disease Control and Prevention
Ouédraogo-Traoré, Rasmata
Burkina Faso, Ouagadougou
Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle
Sangaré, Lassana
Burkina Faso, Ouagadougou
Centre Hospitalier Universitaire
Sanou, Idrissa
Burkina Faso, Bobo-dioulasso
Centre Hospitalier Universitaire Souro Sanou
Kandolo, Denis
Burkina Faso, Ouagadougou
World Health Organization Ouagadougou
Kaboré, Pascal
Burkina Faso, Ouagadougou
Ministere de la Sante Ouagadougou
Clark, Thomas A.
United States, Atlanta
Centers for Disease Control and Prevention
Ouédraogo, Abdoul Salam
Burkina Faso, Bobo-dioulasso
Centre Hospitalier Universitaire Souro Sanou
Absatou, Ki Ba
Burkina Faso, Ouagadougou
Laboratoire National de Santé Publique
Ouédraogo, Charles D.
Burkina Faso, Kaya
Centre Hospitalier Régional de Kaya
Hassan-King, Musa K.A.
France, Ferney-voltaire
Meningitis Vaccine Project
Thomas, Jennifer Dolan
United States, Atlanta
Centers for Disease Control and Prevention
Hatcher, Cynthia P.
United States, Atlanta
Centers for Disease Control and Prevention
Djingarey, Mamoudou Harouna
Burkina Faso, Ouagadougou
World Health Organization Ouagadougou
Messonnier, Nancy E.
United States, Atlanta
Centers for Disease Control and Prevention
Préziosi, Marie Pierre
Switzerland, Geneva
Organisation Mondiale de la Santé
LaForce, F. Marc
France, Ferney-voltaire
Meningitis Vaccine Project
Caugant, Dominique A.
Norway, Oslo
Folkehelseinstituttet
Norway, Oslo
Medisinske Fakultet
Statistics
Citations: 80
Authors: 20
Affiliations: 12
Identifiers
Doi:
10.1128/CVI.00479-10
ISSN:
15566811
e-ISSN:
1556679X
Study Design
Cross Sectional Study
Study Locations
Burkina Faso
Participants Gender
Female